Horizon Quantum Computing to Establish First-of-a-Kind…

NEW YORK and EAST PROVIDENCE, R.I., May 1, 2020 -- HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition of a majority stake in IlluminOss Medical, Inc. ("IlluminOss" or the "Company").

IlluminOss offers a unique and disruptive technology for the orthopedic trauma market. The Company's Photodynamic Bone Stabilization System is a minimally invasive approach for fracture repair and stabilization through a patient-specific intramedullary implant. The system utilizes a light-curable liquid polymer, contained within an expandable balloon, to create a patient-conforming, rigid implant within the bone canal. The technology is particularly suited for the fast-growing elderly patient population. It enables increased stability for osteoporotic and compromised bone, as well as early mobilization. IlluminOss can be also used in conjunction with cleared plates, screws and nails for supplemental fixation in compromised bone.

EAST PROVIDENCE, R.I., Feb. 26, 2019 (GLOBE NEWSWIRE) -- IlluminOss Medical, Inc., a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced the U.S. launch and commercial availability of the IlluminOss® Bone Stabilization System for use in skeletally mature patients in the treatment of traumatic and fragility fractures of the humerus, radius and ulna. IlluminOss recently obtained FDA clearance for these exciting new indications*, having been previously available solely for the treatment of pathological and impending pathological fractures associated with metastatic disease in the U.S. IlluminOss Medical, Inc. will be in Booth #6243 at the AAOS 2019 Annual Meeting in Las Vegas, NV from March 12-16^th and will be presenting data regarding the IlluminOss System on March 13^th at 1:45 pm in Exhibit Hall B at Booth #3032.

EAST PROVIDENCE, RI (July 18, 2016) – IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced it has completed enrollment in its first U.S. clinical trial towards FDA approval of its IlluminOss System, the world's first and only system of its kind which supports the treatment of fractures using patient-specific intramedullary implants. Thirteen surgical sites around the country participated in the trial, which included 80 patients -- all with impending or pathologic fractures in the humerus due to metastatic carcinoma. IlluminOss' minimally invasive procedure incorporates the use of a thin walled PET balloon that is infused with a liquid monomer and inserted into the intramedullary canal of the bone conforming to the shape of the patient's specific bone. The device forms a hardened implant once the surgeon activates the visible light delivered within the PET balloon. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant.

East Providence, RI July 21, 2015 – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced the appointment of Clive V. Ridgwell as vice president of sales. Ridgwell brings more than 30 years of commercial experience in medical device fields which he will apply to the further development of IlluminOss' product strategy in global markets.

EAST PROVIDENCE, RI, Apr 21, 2015 – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced the appointment of Amy Orlick Berman as the company's vice president of clinical affairs. Berman brings almost two decades of clinical affairs experience and has extensive expertise leading global research programs from inception through product approval. In her new position, she will be responsible for the global clinical trial program at IlluminOss, including the U.S. Lightfix trial towards securing approval for the treatment of impeding and actual fractures of the humerus in patients with metastatic bone disease.

Prior to joining IlluminOss, Berman was at Cordis, Johnson & Johnson for nearly 10 years where she held roles of increasing responsibility and oversaw a number of high-profile clinical research programs in the U.S., Europe and Japan.

Light Fix Proximal Humerus Trial Led by Dr. Paul Vegt to Apply IlluminOss’ PatientConforming Implant Technology to Fragility Fractures; First use of New Latitude Radiopaque Markings

East Providence, RI/Dordrecht, Netherlands, (March 24, 2015) – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the first patient has been enrolled at Albert Schweitzer Hospital in the Netherlands as part of its EU Light fix Proximal Humerus Fracture Repair Trial for the treatment of osteoporotic and fragility fractures. The trial at Albert Schweitzer Hospital is being led by Dr. Paul Vegt, M.D., Ph.D, and is an expansion of IlluminOss’ technology in to the treatment of osteoporotic and fragility fractures most common in the elderly.

Light Fix Trial at Vienna General Hospital Will Apply IlluminOss’ Minimally Invasive, Patient-Specific Bone Stabilization Technology

East Providence, RI/Vienna, Austria (March 3, 2015) – IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the first patient has been enrolled in its EU Light Fix trial for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma. The trial will be led by Prof. Reinhard Windhager, MD of the University Clinic of Vienna Orthopaedic Department. Prof. Windhager is a worldleading orthopedic oncologist who heads the Department of Orthopaedic Surgery at Vienna General Hospital (AKH). The EU Light Fix trial will enroll up to 45 patients at approximately 10 centers in Austria, Germany and the Netherlands.

2014 Marked by Continued Success in International Orthopedics Markets and Conditional Clearance for First U.S. Clinical Trial to Begin in 2015
East Providence, RI (December 10, 2014) – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has been issued two new patents related to its internal bone fixation system. IlluminOss now owns 25 issued U.S. patents and its complete intellectual property portfolio includes over 55 issued patents in 17 countries around the world - with many more patent applications Hollister Outlet currently pending related to its revolutionary IlluminOss System for minimally invasive fixation and treatment of broken bones.